Pfizer completed its $67 billion acquisition of Wyeth Pharmaceuticals last fall, just one in a string of recent mergers and acquisitions in the pharma industry. When asked how the two meetings departments would be affected and how procurement and sourcing would be handled, Joan Campion, a spokeswoman for Pfizer, declined to get specific: “I can tell you that Pfizer is continuing to evaluate its global workforce, which includes our medical meetings group, to determine how best to support
Pfizer-Wyeth Merger and Meetings
The Pfizer-Wyeth merger will mean changes for its meetings department. What they may be, however, is still up in the air.